Ser2448
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser2448  -  mTOR (human)

Site Information
RsRtRtDsysAGQsV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447578
Available spectra:  4 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 189 ) , flow cytometry ( 1 ) , immunoprecipitation ( 189 ) , mass spectrometry ( 13 , 15 , 19 , 23 , 28 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 39 , 41 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 63 , 64 , 68 , 69 , 70 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 94 , 95 , 96 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 106 , 107 , 108 , 109 , 110 , 111 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 152 , 153 , 155 , 156 , 157 , 158 , 161 , 162 , 163 ) , mutation of modification site ( 173 , 182 , 188 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 14 , 15 , 16 , 17 , 18 , 20 , 22 , 25 , 26 , 27 , 40 , 62 , 66 , 67 , 93 , 97 , 112 , 113 , 114 , 126 , 127 , 128 , 129 , 151 , 154 , 159 , 160 , 164 , 165 , 166 , 167 , 168 , 169 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 ) , phosphoamino acid analysis ( 115 ) , phosphopeptide mapping ( 189 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 12 , 15 , 16 , 17 , 18 , 20 , 22 , 25 , 27 , 40 , 62 , 93 , 97 , 112 , 113 , 114 , 115 , 127 , 128 , 129 , 151 , 154 , 159 , 160 , 164 , 165 , 166 , 167 , 168 , 169 , 171 , 172 , 175 , 176 , 177 , 178 , 179 , 182 , 183 , 185 , 187 , 188 , 189 )
Disease tissue studied:
adrenal cancer ( 113 ) , adrenocortical carcinoma ( 113 ) , bone cancer ( 62 ) , brain cancer ( 15 , 127 , 128 , 172 ) , glioblastoma ( 15 , 127 , 172 ) , glioblastoma multiforme ( 127 ) , glioma ( 15 , 127 , 172 ) , medulloblastoma ( 128 ) , breast cancer ( 5 , 9 , 14 , 19 , 22 , 27 , 40 , 93 , 97 , 127 , 129 , 151 , 177 ) , breast adenocarcinoma ( 40 ) , HER2 positive breast cancer ( 13 ) , luminal A breast cancer ( 13 ) , luminal B breast cancer ( 13 ) , breast cancer, triple negative ( 13 , 40 ) , cervical cancer ( 5 , 154 ) , cervical squamous cell carcinoma ( 5 , 154 ) , colorectal cancer ( 14 , 26 , 62 , 182 ) , colorectal carcinoma ( 14 , 26 , 62 , 182 ) , gastric cancer ( 12 , 63 , 64 , 68 , 69 , 70 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 89 , 98 , 100 , 101 , 103 , 104 , 116 , 117 , 118 , 119 , 120 , 130 , 163 ) , gastric carcinoma ( 12 , 63 , 64 , 68 , 69 , 70 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 89 , 98 , 100 , 101 , 103 , 104 , 116 , 117 , 118 , 119 , 120 , 130 , 163 ) , leukemia ( 3 , 16 , 94 , 95 , 96 , 108 , 110 , 111 , 125 , 168 , 177 ) , acute myelogenous leukemia ( 3 , 177 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 3 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 3 ) , chronic myelogenous leukemia ( 16 , 94 , 95 , 96 , 108 , 110 , 111 , 125 , 168 ) , liver cancer ( 8 , 175 , 176 ) , hepatocellular carcinoma ( 10 ) , lung cancer ( 6 , 7 , 11 , 20 , 25 , 31 , 32 , 33 , 34 , 35 , 36 , 87 , 88 , 90 , 91 , 99 , 102 , 106 , 107 , 109 , 121 , 130 , 151 , 184 ) , non-small cell lung cancer ( 6 , 7 , 11 , 20 , 25 , 32 , 33 , 35 , 36 , 87 , 88 , 90 , 91 , 99 , 102 , 106 , 107 , 109 , 121 ) , non-small cell lung adenocarcinoma ( 6 , 7 , 11 , 20 , 25 , 32 , 33 , 34 , 35 , 36 , 90 , 91 , 99 , 102 , 106 , 107 , 109 , 121 , 130 ) , non-small cell large cell lung carcinoma ( 6 , 7 , 25 , 32 , 35 ) , non-small cell squamous cell lung carcinoma ( 34 , 90 , 91 , 99 , 102 , 121 , 130 ) , small-cell lung cancer ( 31 ) , lymphoma ( 114 ) , anaplastic large cell lymphoma ( 114 ) , T cell lymphoma ( 114 ) , neuroblastoma ( 23 , 124 ) , ovarian cancer ( 67 , 112 , 180 ) , ovarian epithelial carcinoma ( 67 ) , pancreatic cancer ( 66 , 127 , 182 ) , pancreatic carcinoma ( 127 , 182 ) , multiple myeloma ( 2 ) , prostate cancer ( 4 , 17 , 171 , 188 ) , melanoma skin cancer ( 131 )
Relevant cell line - cell type - tissue:
'brain, cerebellum' ( 128 ) , 'muscle, skeletal' ( 160 , 169 , 175 ) , 'stem, embryonic' ( 142 ) , 293 (epithelial) ( 27 , 151 , 174 , 179 , 188 , 189 ) , 293E (epithelial) ( 173 ) , 293GP (epithelial) ( 16 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 189 ) , A549 (pulmonary) ( 6 , 7 , 20 , 25 , 151 , 184 ) , ADOR (pulmonary) ( 11 ) , adrenal gland ( 113 ) , AGS (gastric) ( 12 ) , AU565 (breast cell) ( 40 ) , BAEC (endothelial) ( 167 ) , BaF3 ('B lymphocyte, precursor') ( 16 ) , breast ( 13 ) , BT-474 (breast cell) ( 14 , 19 ) , BV-173 (myeloid) ( 168 ) , Caco-2 (intestinal) ( 186 ) , Cal-12T (pulmonary) ( 36 ) , Calu-3 (pulmonary) ( 33 ) , cervix ( 154 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 189 ) , Daoy ( 128 ) , DLD1 (intestinal) ( 182 ) , DMS53 (pulmonary) ( 31 ) , DU 145 (prostate cell) ( 4 , 188 ) , FDCP-1 (myeloid) ( 188 ) , fibroblast-skin ( 178 ) , glial-brain ( 15 ) , HaCaT (keratinocyte) ( 115 , 159 ) , HAEC (endothelial) ( 164 ) , HAK-1A (hepatic) ( 10 ) , HAK-1B (hepatic) ( 10 ) , HCC15 (pulmonary) ( 34 ) , HCC44 (pulmonary) ( 36 ) , HCC78 (pulmonary) ( 35 ) , HCC827 (pulmonary) ( 25 , 33 ) , HCT116 (intestinal) ( 14 , 62 , 148 ) , HCT15 (intestinal) ( 26 ) , heart ( 187 ) , HEK293T (epithelial) ( 16 ) , HeLa (cervical) ( 5 , 39 , 62 , 122 , 123 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 150 , 174 ) , HepG2 (hepatic) ( 8 , 144 , 146 , 175 , 176 ) , HGC-27 (gastric) ( 12 ) , HPAC (pancreatic) ( 127 ) , HPCA (prostate cell) ( 17 ) , Jurkat (T lymphocyte) ( 37 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 92 , 149 ) , K562 (erythroid) ( 16 , 94 , 95 , 96 , 108 , 110 , 111 , 125 , 168 ) , Karpas-299 (T lymphocyte) ( 114 ) , Kasumi-1 (myeloid) ( 3 ) , KG-1 (myeloid) ( 3 ) , KG-1a (myeloid) ( 3 ) , KPL-4 (breast cell) ( 40 ) , LAN-6 (neural crest) ( 23 ) , liver ( 28 , 175 ) , LOU-NH91 (squamous) ( 34 ) , lung ( 31 , 32 , 33 , 34 , 35 , 36 , 126 ) , lymphocyte-blood ( 1 ) , MCF-10A (breast cell) ( 27 ) , MCF-7 (breast cell) ( 27 , 40 , 93 , 97 , 129 , 173 , 177 ) , MDA-IBC-3 (breast cell) ( 40 ) , MDA-MB-231 (breast cell) ( 5 , 22 , 40 , 127 , 151 ) , MDA-MB-468 (breast cell) ( 40 , 151 ) , MKN-45 (gastric) ( 41 , 63 , 64 , 68 , 69 , 70 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 89 , 98 , 100 , 101 , 103 , 104 , 116 , 117 , 118 , 119 , 120 , 130 , 161 , 162 , 163 ) , MRC5 (fibroblast) ( 20 ) , MV4-11 (macrophage) ( 148 ) , myocyte-heart ( 183 ) , NB-4 (myeloid) ( 177 , 181 ) , NCI-H1299 (pulmonary) ( 25 , 32 ) , NCI-H1437 (pulmonary) ( 36 ) , NCI-H1650 (pulmonary) ( 33 ) , NCI-H1666 (pulmonary) ( 36 ) , NCI-H1703 (squamous) ( 34 , 41 , 90 , 91 , 99 , 102 , 121 , 130 , 152 , 153 , 158 ) , NCI-H1734 (pulmonary) ( 32 ) , NCI-H1781 (pulmonary) ( 35 ) , NCI-H1944 (pulmonary) ( 32 ) , NCI-H1975 (pulmonary) ( 6 , 7 , 11 , 33 ) , NCI-H2073 (pulmonary) ( 34 ) , NCI-H2106 (pulmonary) ( 33 ) , NCI-H2228 (pulmonary) ( 35 , 145 , 147 ) , NCI-H2342 (pulmonary) ( 34 ) , NCI-H2405 (pulmonary) ( 36 ) , NCI-H295R ( 113 ) , NCI-H3122 (pulmonary) ( 35 ) , NCI-H3255 (pulmonary) ( 41 , 87 , 88 , 130 , 143 , 155 , 156 , 157 ) , NCI-H358 (pulmonary) ( 32 ) , NCI-H441 (pulmonary) ( 106 , 107 , 109 ) , NCI-H446 (pulmonary) ( 31 ) , NCI-H460 (pulmonary) ( 6 , 7 , 25 , 32 ) , NCI-H526 (pulmonary) ( 31 ) , NCI-H661 (pulmonary) ( 35 ) , NCI-H69 (pulmonary) ( 31 ) , NCI-H82 (pulmonary) ( 31 ) , OK (renal) ( 166 ) , ovary ( 67 , 112 , 180 ) , OVCAR4 (ovarian) ( 180 ) , OVCAR5 (ovarian) ( 180 ) , PANC-1 (pancreatic) ( 127 , 182 ) , pancreatic ( 66 ) , PC3 (prostate cell) ( 171 , 188 ) , RPMI-8266 (plasma cell) ( 2 ) , SH-SY5Y (neural crest) ( 23 , 124 ) , SiHa (squamous) ( 5 ) , SK-MEL28 (melanocyte) ( 18 ) , SKBr3 (breast cell) ( 9 , 40 , 127 , 151 ) , skin ( 131 ) , SKOV-3 (ovarian) ( 180 ) , SMS-KCN-A (neural crest) ( 23 ) , SNB-19 (glial) ( 172 ) , SR (T lymphocyte) ( 114 ) , SU-DHL1 (T lymphocyte) ( 114 ) , SUM149 (breast cell) ( 14 , 40 ) , SUM159 (breast cell) ( 40 ) , SUM190 (breast cell) ( 40 ) , SW48 (intestinal) ( 26 ) , SW480 (intestinal) ( 182 ) , SW620 (intestinal) ( 26 ) , U-251 MG (glial) ( 172 ) , U266 (plasma cell) ( 185 ) , U2OS (bone cell) [GR (human)] ( 181 ) , U2OS (bone cell) ( 62 ) , U373 MG (glial) ( 127 ) , U87MG (glial) ( 127 , 172 )

Upstream Regulation
Regulatory protein:
Akt1 (cow) ( 167 ) , Akt1 (human) ( 182 ) , AMPKA1 (human) ( 167 ) , CIP2A (human) ( 27 ) , DUSP6 (human) ( 187 ) , FAK (human) ( 164 ) , mTOR (human) ( 151 ) , Notch 1 (human) ( 170 ) , NuaK1 (human) ( 182 ) , p53 (human) ( 170 ) , RAF1 (human) ( 187 ) , Raptor (human) ( 27 , 151 ) , RICTOR (human) ( 10 , 151 )
Putative in vivo kinases:
Akt1 (human) ( 179 , 188 ) , p70S6K (human) ( 173 , 174 )
Kinases, in vitro:
Akt1 (human) ( 188 , 189 ) , p70S6K (human) ( 173 , 174 )
Treatments:
acadesine ( 159 ) , afatinib ( 11 ) , Akt-I-1 ( 166 ) , aloe-emodin ( 9 ) , amino_acid_starvation ( 189 ) , amino_acids ( 174 ) , anti-HLA ( 164 ) , As2O3 ( 168 ) , AZD8055 ( 10 ) , bicyclol ( 8 ) , Cbz-B3A ( 16 ) , colforsin ( 187 ) , collagen XIX (NC1 domain) ( 18 ) , compound_C ( 159 , 167 ) , cycloheximide ( 178 ) , DMSO ( 165 ) , exercise ( 169 ) , fasting ( 30 ) , GDNF ( 93 ) , gefitinib ( 41 , 130 ) , GSK2334470 ( 2 ) , HGF ( 12 ) , IFN-beta ( 185 ) , IFN-gamma ( 181 , 184 ) , IGF-1 ( 182 ) , IL-24 ( 25 ) , IL-3 ( 188 ) , imatinib ( 41 ) , insulin ( 30 , 151 , 160 , 173 , 175 , 176 , 179 , 187 , 188 , 189 ) , JQ1 ( 3 ) , L-glutamine_withdrawal ( 5 ) , laminar flow ( 167 ) , liothyronine ( 178 ) , LLL12 ( 127 ) , LPS ( 184 ) , LY294002 ( 115 , 178 , 182 , 184 , 185 ) , metformin ( 97 ) , methyl-beta-cyclodextrin ( 115 ) , MYH1485 ( 4 ) , nocodazole ( 179 ) , oscillatory_flow ( 167 ) , OSI-027 ( 105 ) , osteopontin ( 129 ) , OSU-03012 ( 15 ) , ouabain ( 166 ) , pemetrexed ( 6 , 7 , 14 ) , phorbol_ester ( 173 , 187 ) , pimenta doica ( 22 ) , PP2 ( 164 ) , PP242 ( 2 , 26 ) , pravastatin ( 176 ) , QLT0267 ( 172 ) , RAD001 ( 10 ) , rapamycin ( 4 , 10 , 16 , 97 , 105 , 129 , 151 , 173 , 174 , 175 , 185 , 187 , 189 ) , resveratrol ( 1 ) , retinoic_acid ( 177 ) , RGD ( 183 ) , SB202190 ( 187 ) , SB203580 ( 187 ) , selenite ( 171 ) , serum ( 174 , 188 ) , sildenafil ( 6 , 7 , 11 ) , siRNA ( 151 , 182 ) , sorafenib ( 6 , 11 , 14 ) , Su11274 ( 41 , 130 ) , SU6656 ( 165 ) , sunitinib ( 128 ) , triptolide ( 17 ) , U0126 ( 166 , 187 ) , UV ( 159 ) , virus infection ( 20 ) , wortmannin ( 115 , 167 , 173 , 174 , 178 , 184 , 188 , 189 )

Downstream Regulation
Effects of modification on mTOR:
enzymatic activity, induced ( 154 , 184 ) , intracellular localization ( 154 )

Disease / Diagnostics Relevance
Relevant diseases:
adrenocortical carcinoma ( 113 ) , cervical squamous cell carcinoma ( 154 ) , ovarian cancer ( 180 ) , ovarian epithelial carcinoma ( 67 ) , pancreatic cancer ( 66 )

References 

1

Craveiro M, et al. (2017) Resveratrol stimulates the metabolic reprogramming of human CD4+ T cells to enhance effector function. Sci Signal 10
29042482   Curated Info

2

Yang C, et al. (2017) PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Oncotarget 8, 39185-39197
28402933   Curated Info

3

Jang JE, et al. (2017) AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells. Clin Cancer Res 23, 2781-2794
27864418   Curated Info

4

Wang Z, et al. (2017) Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway. Oncotarget 8, 22563-22580
28186966   Curated Info

5

Cacace A, Sboarina M, Vazeille T, Sonveaux P (2017) Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism. Oncogene 36, 2074-2084
27748760   Curated Info

6

Booth L, Roberts JL, Poklepovic A, Dent P (2017) PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget 8, 13464-13475
28088782   Curated Info

7

Booth L, et al. (2017) PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget 8, 1449-1468
27903966   Curated Info

8

Wang Y, et al. (2016) Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer 16, 742
27654866   Curated Info

9

Ma JW, et al. (2016) Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. Oncotarget 7, 58915-58930
27391337   Curated Info

10

Watari K, et al. (2016) Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget 7, 47403-47417
27329724   Curated Info

11

Booth L, et al. (2016) Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. Oncotarget 7, 40398-40417
27259258   Curated Info

12

Wu Y, et al. (2016) PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells. Oncotarget 7, 34190-200
27147579   Curated Info

13

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

14

Booth L, et al. (2016) [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget 7, 23608-32
27015562   Curated Info

15

Booth L, et al. (2016) Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget 7, 12975-96
26887051   Curated Info

16

Coffey RT, et al. (2016) Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling. J Biol Chem 291, 5221-33
26740621   Curated Info

17

Zhao F, et al. (2016) Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells. Oncotarget 7, 5366-82
26734992   Curated Info

18

Oudart JB, et al. (2016) The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction. Oncotarget 7, 1516-28
26621838   Curated Info

19

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

20

Klein SR, et al. (2015) C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene 34, 5295-301
25619840   Curated Info

21

Panneerselvam J, et al. (2015) Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget 6, 16271-86
26009991   Curated Info

22

Zhang L, et al. (2015) Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice. Oncotarget 6, 16379-95
25945840   Curated Info

23

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

24

Carpenter RL, Paw I, Dewhirst MW, Lo HW (2015) Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Oncogene 34, 546-57
24469056   Curated Info

25

Panneerselvam J, et al. (2015) IL-24 Inhibits Lung Cancer Cell Migration and Invasion by Disrupting The SDF-1/CXCR4 Signaling Axis. PLoS One 10, e0122439
25775124   Curated Info

26

Ducker GS, et al. (2014) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 33, 1590-600
23542178   Curated Info

27

Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27
24590173   Curated Info

28

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

29

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

30

Vendelbo MH, et al. (2014) Fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling. PLoS One 9, e102031
25020061   Curated Info

31

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

32

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

33

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

34

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

35

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

36

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

37

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

38

Lin JF, et al. (2013) Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling. Carcinogenesis 34, 406-14
23172666   Curated Info

39

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

40

Robertson FM, et al. (2013) Presence of anaplastic lymphoma kinase in inflammatory breast cancer. Springerplus 2, 497
24102046   Curated Info

41

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

42

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

43

Rho SB, et al. (2012) Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal 24, 131-9
21893193   Curated Info

44

Rikova K (2011) CST Curation Set: 13123; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

45

Rikova K (2011) CST Curation Set: 13125; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

46

Rikova K (2011) CST Curation Set: 13127; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

47

Rikova K (2011) CST Curation Set: 13128; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

48

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

49

Rikova K (2011) CST Curation Set: 13130; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

50

Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Rikova K (2011) CST Curation Set: 13132; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

52

Liu J, et al. (2011) PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol 31, 4917-27
21986499   Curated Info

53

Mulhern D (2011) CST Curation Set: 12742; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

54

Mulhern D (2011) CST Curation Set: 12743; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

55

Mulhern D (2011) CST Curation Set: 12745; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

56

Mulhern D (2011) CST Curation Set: 12748; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

57

Mulhern D (2011) CST Curation Set: 12749; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

58

Mulhern D (2011) CST Curation Set: 12750; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

59

Mulhern D (2011) CST Curation Set: 12751; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

60

Mulhern D (2011) CST Curation Set: 12754; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

61

Rosner M, Hengstschläger M (2011) Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene 30, 4509-22
21602892   Curated Info

62

Malik SA, et al. (2011) BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 30, 3918-29
21460857   Curated Info

63

Moritz A (2011) CST Curation Set: 12042; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

64

Moritz A (2011) CST Curation Set: 12051; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

65

Wang H, et al. (2011) Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol 186, 5217-26
21422248   Curated Info

66

Kennedy AL, et al. (2011) Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42, 36-49
21474066   Curated Info

67

No JH, et al. (2011) Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol 121, 8-12
21276607   Curated Info

68

Guo A (2011) CST Curation Set: 11299; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

69

Guo A (2011) CST Curation Set: 11301; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

70

Possemato A (2011) CST Curation Set: 11326; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

71

Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71
21281788   Curated Info

72

Yung HW, Charnock-Jones DS, Burton GJ (2011) Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 6, e17894
21445305   Curated Info

73

Possemato A (2010) CST Curation Set: 10783; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

74

Possemato A (2010) CST Curation Set: 10790; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

75

Possemato A (2010) CST Curation Set: 10781; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

76

Possemato A (2010) CST Curation Set: 10782; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

77

Possemato A (2010) CST Curation Set: 10793; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

78

Possemato A (2010) CST Curation Set: 10780; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

79

Possemato A (2010) CST Curation Set: 10731; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

80

Moritz A (2010) CST Curation Set: 10611; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

81

Moritz A (2010) CST Curation Set: 10617; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

82

Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

83

Moritz A (2010) CST Curation Set: 10604; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

84

Moritz A (2010) CST Curation Set: 10607; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

85

Moritz A (2010) CST Curation Set: 10608; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

86

Moritz A (2010) CST Curation Set: 10601; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

87

Moritz A (2010) CST Curation Set: 10599; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

88

Moritz A (2010) CST Curation Set: 10597; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

89

Moritz A (2010) CST Curation Set: 10600; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

90

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

91

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

92

Possemato A (2010) CST Curation Set: 10531; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

93

Plaza-Menacho I, et al. (2010) Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29, 4648-57
20531297   Curated Info

94

Beausoleil S (2010) CST Curation Set: 10285; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

95

Beausoleil S (2010) CST Curation Set: 10278; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

96

Beausoleil S (2010) CST Curation Set: 10280; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

97

Zakikhani M, Blouin MJ, Piura E, Pollak MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123, 271-9
20135346   Curated Info

98

Moritz A (2010) CST Curation Set: 10238; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

99

Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

100

Moritz A (2010) CST Curation Set: 10232; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

101

Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

102

Moritz A (2010) CST Curation Set: 10239; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

103

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

104

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

105

Carayol N, et al. (2010) Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 107, 12469-74
20616057   Curated Info

106

Moritz A (2010) CST Curation Set: 9985; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

107

Moritz A (2010) CST Curation Set: 9984; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

108

Moritz A (2010) CST Curation Set: 10026; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

109

Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

110

Moritz A (2010) CST Curation Set: 10025; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

111

Moritz A (2010) CST Curation Set: 10024; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

112

Bunkholt Elstrand M, et al. (2010) Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol 41, 794-804
20153512   Curated Info

113

Doghman M, et al. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 70, 4666-75
20484036   Curated Info

114

Anastasov N, et al. (2010) C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica 95, 760-7
20015877   Curated Info

115

Calay D, et al. (2010) Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J Invest Dermatol 130, 1136-45
20054340   Curated Info

116

Moritz A (2010) CST Curation Set: 9374; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

117

Moritz A (2010) CST Curation Set: 9373; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

118

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

119

Moritz A (2010) CST Curation Set: 9281; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

120

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

121

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

122

Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

123

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

124

Rikova K (2010) CST Curation Set: 9209; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

125

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

126

Yoshizawa A, et al. (2010) Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16, 240-8
20008839   Curated Info

127

Lin L, et al. (2010) A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12, 39-50
20072652   Curated Info

128

Yang F, et al. (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8, 35-45
20053726   Curated Info

129

Ahmed M, Kundu GC (2010) Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer 9, 101
20459645   Curated Info

130

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

131

Tucker M (2009) CST Curation Set: 8371; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

132

Zhou J (2009) CST Curation Set: 7636; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

133

Zhou J (2009) CST Curation Set: 7633; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

134

Zhou J (2009) CST Curation Set: 7637; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

135

Zhou J (2009) CST Curation Set: 7635; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

136

Zhou J (2009) CST Curation Set: 7634; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

137

Zhou J (2009) CST Curation Set: 7638; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

138

Zhou J (2009) CST Curation Set: 7602; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

139

Zhou J (2009) CST Curation Set: 7601; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

140

Zhou J (2009) CST Curation Set: 7603; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

141

Zhou J (2009) CST Curation Set: 7604; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

142

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

143

Possemato A (2009) CST Curation Set: 7323; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

144

Possemato A (2009) CST Curation Set: 7319; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

145

Possemato A (2009) CST Curation Set: 7320; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

146

Possemato A (2009) CST Curation Set: 7318; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

147

Possemato A (2009) CST Curation Set: 7321; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

148

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

149

Possemato A (2009) CST Curation Set: 7263; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

150

Zhou J (2009) CST Curation Set: 6365; Year: 2009; Biosample/Treatment: cell line, HeLa/EGF; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

151

Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69, 1821-7
19244117   Curated Info

152

Moritz A (2009) CST Curation Set: 5895; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

153

Moritz A (2009) CST Curation Set: 5889; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

154

Feng W, et al. (2009) Morphoproteomic Evidence of Constitutively Activated and Overexpressed mTOR Pathway in Cervical Squamous Carcinoma and High Grade Squamous Intraepithelial Lesions. Int J Clin Exp Pathol 2, 249-60
19079619   Curated Info

155

Moritz A (2008) CST Curation Set: 5661; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

156

Moritz A (2008) CST Curation Set: 5655; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

157

Moritz A (2008) CST Curation Set: 5658; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

158

Moritz A (2008) CST Curation Set: 5445; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

159

Cao C, et al. (2008) AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytes. J Biol Chem 283, 28897-908
18715874   Curated Info

160

Greenhaff PL, et al. (2008) Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 295, E595-604
18577697   Curated Info

161

Rush J (2008) CST Curation Set: 4498; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated &'||' normal; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

162

Rush J (2008) CST Curation Set: 4490; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated &'||' normal; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

163

Moritz A (2008) CST Curation Set: 4208; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

164

Jindra PT, Jin YP, Rozengurt E, Reed EF (2008) HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 180, 2357-66
18250445   Curated Info

165

Vojtechová M, et al. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10, 99-107
18283331   Curated Info

166

Khundmiri SJ, et al. (2007) Ouabain stimulates protein kinase B (Akt) phosphorylation in opossum kidney proximal tubule cells through an ERK-dependent pathway. Am J Physiol Cell Physiol 293, C1171-80
17634416   Curated Info

167

Guo D, Chien S, Shyy JY (2007) Regulation of endothelial cell cycle by laminar versus oscillatory flow: distinct modes of interactions of AMP-activated protein kinase and Akt pathways. Circ Res 100, 564-71
17272808   Curated Info

168

Yoon P, et al. (2006) Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 5, 2815-23
17121928   Curated Info

169

Dreyer HC, et al. (2006) Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. J Physiol 576, 613-24
16873412   Curated Info

170

Mungamuri SK, Yang X, Thor AD, Somasundaram K (2006) Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66, 4715-24
16651424   Curated Info

171

Wu Y, et al. (2006) Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 5, 246-52
16505097   Curated Info

172

Koul D, et al. (2005) Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4, 1681-8
16275989   Curated Info

173

Holz MK, Blenis J (2005) Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280, 26089-93
15905173   Curated Info

174

Chiang GG, Abraham RT (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280, 25485-90
15899889   Curated Info

175

Khamzina L, Veilleux A, Bergeron S, Marette A (2005) Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 146, 1473-81
15604215   Curated Info

176

Pääjärvi G, et al. (2005) HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J 19, 476-8
15625077   Curated Info

177

Lal L, et al. (2005) Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 105, 1669-77
15471950   Curated Info

178

Cao X, et al. (2005) Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 19, 102-12
15388791   Curated Info

179

Asnaghi L, et al. (2004) Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 23, 5781-91
15208671   Curated Info

180

Altomare DA, et al. (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853-7
15208673   Curated Info

181

Lekmine F, et al. (2004) Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 295, 173-82
15051500   Curated Info

182

Suzuki A, et al. (2004) ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 24, 3526-35
15060171   Curated Info

183

Balasubramanian S, Kuppuswamy D (2003) RGD-containing peptides activate S6K1 through beta3 integrin in adult cardiac muscle cells. J Biol Chem 278, 42214-24
12909616   Curated Info

184

Kristof AS, Marks-Konczalik J, Billings E, Moss J (2003) Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. J Biol Chem 278, 33637-44
12807916   Curated Info

185

Lekmine F, et al. (2003) Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 278, 27772-80
12759354   Curated Info

186

Bettoun DJ, et al. (2002) A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J Biol Chem 277, 24847-50
12036952   Curated Info

187

Iijima Y, et al. (2002) c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 277, 23065-75
11940578   Curated Info

188

Sekulić A, et al. (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60, 3504-13
10910062   Curated Info

189

Navé BT, et al. (1999) Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344 Pt 2, 427-31
10567225   Curated Info